Post by
rgonlyfactspls on Nov 05, 2014 9:22pm
A backhanded 20-fold target population estimate/concern....
by the FDA?!? Versus what Bioniche went in with. What is that informal endorsement of market potential worth in negotiation$ with potential partners? And, HighteawithIntrepid full marks to your logic but I believe you missed a potential 20-fold point in your calculation. A "treatment" does not consist of one dose. Taylor Collison's Feb-11 report estimated Urocidin's "average dosing regimen" at up to 21 doses over 2 years. Tanya Maciver's April-10 had the "average course of therapy" at 15 doses. I would have included the new revenue figure but my calculator keeps showing an error me$$age. Let the "partnering" negotiations now turn up a few notches! rg
Comment by
enriquesuave on Nov 05, 2014 9:38pm
Right on! This is great news, even better than becoming an Orphan Status drug which is under 200000 patients. FDA expects them to treat more than 200000 patients, or else would have granted OS. They must see this drug as a step up above BCG, or at least an alternate choice with superior results. IMHO